Pussard E, Verdier F, Faurisson F, Scherrmann J M, Le Bras J, Blayo M C
INSERM U13, Hôpital Claude Bernard, Paris, France.
Eur J Clin Pharmacol. 1987;33(4):409-14. doi: 10.1007/BF00637639.
The disposition of monodesethylamodiaquine was studied in four healthy subjects after a single oral dose of 10 mg/kg amodiaquine base. Amodiaquine was not found in any sample, but the major metabolite monodesethylamodiaquine was detected and was assumed to be the sole derivative that contributed significantly to antimalarial activity in the blood. The best fit for the decay of the metabolite was obtained with a three-compartment model. The half-lives of the first two phases were 3.2 to 11.4 h for t1/2 alpha 1 and 22.7 to 50.3 h for t1/2 alpha 2 in plasma. The half-life of the terminal phase (t1/2 beta) was between 9 and 18.2 days. The concentration in whole blood was 4- to 6-times higher than in plasma. Three schedules (alternate days, weekly, daily) of the conventional prophylactic dose of 10 mg/kg per week were compared in six other healthy subjects. There were significant differences in the plasma monodesethylamodiaquine levels between the three schedules.
在4名健康受试者单次口服10mg/kg阿莫地喹碱后,对单去乙基阿莫地喹的处置情况进行了研究。在任何样本中均未检测到阿莫地喹,但检测到了主要代谢产物单去乙基阿莫地喹,并且假定它是血液中抗疟活性的唯一显著贡献衍生物。用三室模型能最好地拟合该代谢产物的衰减情况。血浆中前两个相的半衰期,t1/2α1为3.2至11.4小时,t1/2α2为22.7至50.3小时。终末相(t1/2β)的半衰期在9至18.2天之间。全血中的浓度比血浆中的高4至6倍。在另外6名健康受试者中比较了三种给药方案(隔天、每周、每天),常规预防剂量为每周10mg/kg。三种给药方案之间的血浆单去乙基阿莫地喹水平存在显著差异。